Clinical use of biomarkers for toxicant-induced acute kidney injury

Biomarkers in Medicine

Volumn 7, Issue 3, 2013, Pages 441-456

  Pianta, Timothy J ^a,b   Buckley, Nicholas A ^b   Peake, Philip W ^a   Endre, Zoltan H ^a,b,c  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

acute kidney injury; biological markers; cystatin C; drug toxicity; translational medical research

Indexed keywords

AMINOGLYCOSIDE; BIOLOGICAL MARKER; CISPLATIN; CLUSTERIN; CONTRAST MEDIUM; CYSTATIN C; INTERLEUKIN 18; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN KIM 1; PROTEIN L FABP; PROTEIN TFF3; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ALBUMINURIA; BIOASSAY; CLINICAL EVALUATION; CLINICAL PRACTICE; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HUMAN; INTERVENTION STUDY; INTRACELLULAR SIGNALING; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEINURIA; REVIEW; RISK ASSESSMENT; STAPHYLOCOCCUS INFECTION; URINE LEVEL;

ACUTE KIDNEY INJURY; ANIMALS; BIOLOGICAL MARKERS; DRUG TOXICITY; HUMANS; PROGNOSIS;

EID: 84878743472     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.51     Document Type: Review

References (119)

1. Endre ZH, Pickering JW, Walker RJ. Clearance and beyond: the complementary roles of GFR measurement and injury biomarkers in acute kidney injury (AKI). Am. J. Physiol. Renal Physiol. 301(4), F697-F707 (2011).
2. Dieterle F, Sistare F, Goodsaid F et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat. Biotech. 28(5), 455-462 (2010).
3. Abuelo JG. Normotensive ischemic acute renal failure. N. Engl. J. Med. 357(8), 797-805 (2007).
4. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat. Rev. Nephrol. 6(8), 461-470 (2010).
5. Ozer JS, Dieterle F, Troth S et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat. Biotech. 28(5), 486-494 (2010).
6. Cox KM, Goel S, O'Connell RL et al. Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Intern. Med. J. 41(2), 172-178 (2011).
7. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 73(9), 994-1007 (2008).
8. Jiang M. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J. Pharmacol. Exp. Ther. 327, 300-307 (2008).
9. Hanigan MH, Townsend DM, Cooper AJ. Metabolism of cisplatin to a nephrotoxin. Toxicology 257(3), 174-175; author reply 176-177 (2009).
10. Yu F, Megyesi J, Safirstein R. Involvement of the CDK2-E2F1 pathway in cisplatin cytotoxicity in vitro and in vivo. Am. J. Physiol. Renal Physiol. 293, F52-F59 (2007).
11. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am. J. Physiol. Renal Physiol. 289(1), F166-F174 (2005).
12. Zhou H, Kato A, Miyaji T et al. Urinary marker for oxidative stress in kidneys in cisplatin-induced acute renal failure in rats. Nephrol. Dial. Transplant. 21(3), 616-623 (2006).
13. Linkermann A, Himmerkus N, Rölver L et al. Renal tubular Fas ligand mediates fratricide in cisplatin-induced acute kidney failure. Kidney Int. 79(2), 169-178 (2010).
14. Periyasamy-Thandavan S, Jiang M, Wei Q, Smith R, Yin X-M, Dong Z. Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int. 74(5), 631-640 (2008).
15. Schmitz C, Hilpert J, Jacobsen C et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J. Biol. Chem. 277(1), 618-622 (2002).
16. Sandoval RM, Molitoris BA. Gentamicin traffics retrograde through the secretory pathway and is released in the cytosol via the endoplasmic reticulum. Am. J. Physiol. Renal Physiol. 286(4), F617-F624 (2004).
17. Denamur S, Tyteca D, Marchand-Brynaert J et al. Role of oxidative stress in lysosomal membrane permeabilization and apoptosis induced by gentamicin, an aminoglycoside antibiotic. Free Radic. Biol. Med. 51(9), 1656-1665 (2011).
18. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am. J. Med. 123(2), 182.e1 (2010).
19. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N. Engl. J. Med. 343(3), 180-184 (2000).
20. Webb JG, Pate GE, Humphries KH et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am. Heart J. 148(3), 422-429 (2004).
21. Matheis K, Laurie D, Andriamandroso C et al. A generic operational strategy to qualify translational safety biomarkers. Drug Discov. Today 16(13-14), 600-608 (2011).
22. Dieterle F, Perentes E, Cordier A et al. Urinary clusterin, cystatin C, b2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat. Biotech. 28(5), 463-469 (2010).
23. Yu Y, Jin H, Holder D et al. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat. Biotech. 28(5), 470-477 (2010).
24. Vaidya VS, Ozer JS, Dieterle F et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat. Biotech. 28(5), 478-485 (2010).
25. Harpur E, Ennulat D, Hoffman D et al. Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat. Toxicol. Sci. 122(2), 235-252 (2011).
26. Ralib AM, Pickering JW, Shaw GM et al. Test characteristics of urinary biomarkers depend on quantitation method in acute kidney injury. J. Am. Soc. Nephrol. 23(2), 322-333 (2012).
27. Grubb A, Blirup-Jensen S, Lindström V, Schmidt C, Althaus H, Zegers I. First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin. Chem. Lab. Med. 48(11), 1619-1621 (2010).
28. Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ 324(7336), 539-541 (2002).
29. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2(Suppl.), 1-138 (2012).
30. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative Workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 8(4), R204-R212 (2004).
31. Mehta RL, Kellum JA, Shah SV et al.; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11(2), R31 (2007).
32. Haase M, Devarajan P, Haase-Fielitz A et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury. J. Am. Coll. Cardiol. 57(17), 1752-1761 (2011).
33. Nickolas TL, Schmidt-Ott KM, Canetta P et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J. Am. Coll. Cardiol. 59(3), 246-255 (2012).
34. Pickering JW, Endre ZH. Linking injury to outcome in acute kidney injury: a matter of sensitivity. PLoS ONE 8(4), e62691 (2013).
35. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837-845 (1988).
36. Pickering JW, Endre ZH. New metrics for assessing diagnostic potential of candidate biomarkers. Clin. J. Am. Soc. Nephrol. 7, 1355-1364 (2012).
37. Endre ZH, Walker RJ, Pickering JW et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int. 77(11), 1020-1030 (2010).
38. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 73(9), 1008-1016 (2008).
39. Schentag JJ, Plaut ME. Patterns of urinary beta 2-microglobulin excretion by patients treated with aminoglycosides. Kidney Int. 17(5), 654-661 (1980).
40. Briggs JP. The hunt for the perfect biomarker for acute kidney injury: back to gamma-trace? Kidney Int. 74(8), 987-989 (2008).
41. Inker LA, Schmid CH, Tighiouart H et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N. Engl. J. Med. 367(1), 20-29 (2012).
42. Grubb A, Nyman U, Björk J. Improved estimation of glomerular filtration rate (GFR) by comparison of eGFR cystatin C and eGFR creatinine. Scand. J. Clin. Lab. Invest. 72(1), 73-77 (2012).
43. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E et al. Could neutrophil-gelatinase-associated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values? Kidney Blood Press. Res. 30(6), 408-415 (2007).
44. Briguori C, Visconti G, Rivera NV et al. Cystatin C and contrast-induced acute kidney injury. Circulation 121(19), 2117-2122 (2010).
45. Ribichini F, Gambaro G, Graziani MS et al. Comparison of serum creatinine and cystatin c for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions. Clin. Chem. 58(2), 458-464 (2012).
46. Mercieri M, Mercieri A, Tritapepe L et al. High-dose aprotinin with gentamicin-vancomycin antibiotic prophylaxis increases blood concentrations of creatinine and cystatin C in patients undergoing coronary artery bypass grafting. Br. J. Anaesth. 82(4), 531-536 (1999).
47. Bárdi E, Bobok I, Oláh AV, Oláh E, Kappelmayer J, Kiss C. Cystatin C is a suitable marker of glomerular function in children with cancer. Pediatr. Nephrol. 19(10), 1145-1147 (2004).
48. Risch L, Herklotz R, Blumberg A, Huber AR. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin. Chem. 47(11), 2055-2059 (2001).
49. Otsuka T, Tanaka A, Suemaru K et al. Evaluation of the clinical application of cystatin C, a new marker of the glomerular filtration rate, for the initial dose-setting of arbekacin. J. Clin. Pharm. Ther. 33(3), 227-235 (2008).
50. Stabuc B, Vrhovec L, Stabuc-Silih M, Cizej TE. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin. Chem. 46(2), 193-197 (2000).
51. Hermida J, Tutor JC. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Ther. Drug Monit. 28(3), 326-331 (2006).
52. Suzuki A, Imanishi Y, Nakano S et al. Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients. J. Pharm. Pharmacol. 62(7), 901-907 (2010).
53. Bodnar L, Wcislo GB, Smoter M et al. Cystatin C as a parameter of glomerular filtration rate in patients with ovarian cancer. Kidney Blood Press. Res. 33(5), 360-367 (2010).
54. Kos J, Stabuc B, Cimerman N, Brünner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin. Chem. 44(12), 2556-2557 (1998).
55. Nielsen EI, Sandström M, Honoré PH, Ewald U, Friberg LE. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin. Pharmacokinet. 48(4), 253-263 (2009).
56. Jones TE, Peter JV, Field J. Aminoglycoside clearance is a good estimate of creatinine clearance in intensive care unit patients. Anaesth. Intensive Care 37(6), 944 (2009).
57. Soulsby N, Greville H, Coulthard K, Doecke C. What is the best method for measuring renal function in adults and children with cystic fibrosis? J. Cyst. Fibros. 9(2), 124-129 (2010).
58. Paragas N, Qiu A, Zhang Q et al. The NGAL reporter mouse detects the response of the kidney to injury in real time. Nat. Med. 17(2), 216-222 (2011).
59. Mori K, Lee HT, Rapoport D et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest. 115(3), 610-621 (2005).
60. McCullough PA, Williams FJ, Stivers DN et al. Neutrophil gelatinase-associated lipocalin: a novel marker of contrast nephropathy risk. Am. J. Nephrol. 35(6), 509-514 (2012).
61. Hirsch R, Dent C, Pfriem H et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr. Nephrol. 22(12), 2089-2095 (2007).
62. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E et al. NGAL (neutrophil-gelatinase-associated lipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine? Int. J. Cardiol. 127(2), 290-291 (2008).
63. Liu X-L, Wang Z-J, Yang Q et al. Plasma neutrophil-gelatinase-associated lipocalin and cystatin C could early diagnose contrast-induced acute kidney injury in patients with renal insufficiency undergoing an elective percutaneous coronary intervention. Chin. Med. J. (Engl.) 125(6), 1051-1056 (2012).
64. Ling W, Zhaohui N, Ben H et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron. Clin. Pract. 108(3), c176-c181 (2008).
65. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A; NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Dis. 54(6), 1012-1024 (2009).
66. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am. J. Nephrol. 26(3), 287-292 (2006).
67. Gaspari F, Cravedi P, Mandalà M et al. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase- associated lipocalin excretion: a pilot prospective case-control study. Nephron. Clin. Pract. 115(2), c154-c160 (2010).
68. Piccioni M, Al-Ismaili Z, Devarajan P et al. Biomarkers of cisplatin and ifosfamide nephrotoxicity in children. J. Am. Soc. Nephrol. 22, 360A (2011)
69. McWilliam SJ, Antoine DJ, Sabbisetti V et al. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS ONE 7(8), e43809 (2012).
70. Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, Malyszko JS, Dobrzycki S. Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Ren. Fail. 31(10), 910-919 (2009).
71. Eisenhart E, Benson S, Lacombe P et al. Safety of low volume iodinated contrast administration for arteriovenous fistula intervention in chronic kidney disease stage 4 or 5 utilizing a bicarbonate prophylaxis strategy. Semin. Dial. 23(6), 638-642 (2010).
72. Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J. Clin. Invest. 118(5), 1657-1668 (2008).
73. Vaidya VS, Ford GM, Waikar SS et al. A rapid urine test for early detection of kidney injury. Kidney Int. 76(1), 108-114 (2009).
74. Nozaki Y, Kinoshita K, Yano T et al. Signaling through the interleukin-18 receptor attenuates inflammation in cisplatin-induced acute kidney injury. Kidney Int. 82(8), 892-902 (2012).
75. Hall IE, Yarlagadda SG, Coca SG et al. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J. Am. Soc. Nephrol. 21(1), 189-197 (2010).
76. Bulent Gul C, Gullulu M, Oral B et al. Urinary IL-18: a marker of contrast-induced nephropathy following percutaneous coronary intervention? Clin. Biochem. 41(7-8), 544-547 (2008).
77. Matsui K, Kamijo-Ikemorif A, Sugaya T, Yasuda T, Kimura K. Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity. Am. J. Pathol. 178(3), 12-12 (2011).
78. Portilla D, Dent C, Sugaya T et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 73(4), 465-472 (2008).
79. Negishi K, Noiri E, Sugaya T et al. A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure. Kidney Int. 72(3), 348-358 (2007).
80. Harel-Sterling M, Ho J, Gao A et al. Biomarkers of acute kidney injury in children treated with cisplatin, carboplatin, and ifosfamide. J. Am. Soc. Nephrol. 23, 650A (2012).
81. Nakamura T, Sugaya T, Node K, Ueda Y, Koide H. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am. J. Kidney Dis. 47(3), 439-444 (2006).
82. Ohta S, Ishimitsu T, Minami J, Ono H. [Effects of intravascular contrast media on urinary excretion of liver fatty acid-binding protein]. Nippon Jinzo Gakkai Shi 47(4), 437-444 (2005).
83. Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S. NGAL (neutrophil gelatinase-associated lipocalin) and L-FABP after percutaneous coronary interventions due to unstable angina in patients with normal serum creatinine. Adv. Med. Sci. 54(2), 221-224 (2009).
84. Fukuda Y, Miura S, Zhang B, Iwata A, Kawamura A. Significance of urinary liver-fatty acid-binding protein in cardiac catheterization in patients with coronary artery disease. Intern. Med. 48(19), 1731-1737 (2009).
85. Kaseda R, Iino N, Hosojima M et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells. Biochem. Biophys. Res. Commun. 357(4), 1130-1134 (2007).
86. Nejat M, Hill JV, Pickering JW, Edelstein CL, Devarajan P, Endre ZH. Albuminuria increases cystatin C excretion: implications for urinary biomarkers. Nephrol. Dial. Transplant. 27(Suppl. 3), iii96-iii103 (2011).
87. Walenkamp GH, Vree TB, Guelen PJ, Jongman-Nix B. Interaction between the renal excretion rates of beta 2-microglobulin and gentamicin in man. Potentials of beta 2-microglobulin excretion as an early prediction of gentamicin induced nephrotoxicity. Clin. Chim. Acta 127(2), 229-238 (1983).
88. Stacul F, Carraro M, Magnaldi S, Faccini L, Guarnieri G, Palma LD. Contrast agent nephrotoxicity: comparison of ionic and nonionic contrast agents. Am. J. Roentgenol. 149(6), 1287-1289 (1987).
89. Daugaard G, Rossing N, Rørth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother. Pharmacol. 21(2), 163-167 (1987).
90. Christensen EI, Birn H, Rippe B, Maunsbach AB. Controversies in nephrology: renal albumin handling, facts, and artifacts! Kidney Int. 72(10), 1192-1194 (2007).
91. Russo LM, Sandoval RM, McKee M et al. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int. 71(6), 504-513 (2007).
92. Levin A, Pate GE, Shalansky S et al. N-acetylcysteine reduces urinary albumin excretion following contrast administration: evidence of biological effect. Nephrol. Dial. Transplant. 22(9), 2520-2524 (2007).
93. Tugay S, Bircan Z, Çaglayan Ç, Arisoy AE, Gökalp AS. Acute effects of gentamicin on glomerular and tubular functions in preterm neonates. Pediatr. Nephrol. 21(10), 1389-1392 (2006).
94. Kent AL, Brown L, Broom M, Broomfield A, Dahlstrom JE. Increased urinary podocytes following indomethacin suggests drug-induced glomerular injury. Pediatr. Nephrol. 27(7), 1111-1117 (2012).
95. Endre ZH, Pickering JW. Outcome definitions in non-dialysis intervention and prevention trials in acute kidney injury (AKI). Nephrol. Dial. Transplant. 25(1), 107-118 (2010).
96. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 80(8), 806-821 (2011).
97. Manabe K, Kamihata H, Motohiro M, Senoo T, Yoshida S, Iwasaka T. Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury. Eur. J. Clin. Invest. 42(5), 557-563 (2012).
98. Makris K, Demponeras C, Zoubouloglou F et al. The role of urinary NGAL to urinary creatinine ratio in the early detection of contrast agent induced acute kidney injury after coronary artery angiography. Presented at: American Association for Clinical Chemistry 2009. Chicago, IL, USA, 19-23 July 2009.
99. Ogi M, Iwase N, Kitamura T et al. [Risk factors for contrast nephropathy in diabetic patients undergoing cardioangiography]. Nippon Jinzo Gakkai Shi 35(2), 161-170 (1993).
100. Endre ZH, Kellum JA, Di Somma S et al.; for the ADQI 10 Workgroup. Differential diagnosis of AKI in clinical practice by functional and damage biomarkers: workgroup statements from the Tenth Acute Dialysis Quality Initiative Consensus Conference. In: ADQI Consensus on AKI Biomarkers and Cardiorenal Syndromes. Contributions to Nephrology (Volume 182). Kellum JA, McCullough PA, Mehta RL, Murray PT, Ronco C (Eds). Karger, Switzerland, 30-44 (2013).
101. Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J. Am. Soc. Nephrol. 15(2), 407-410 (2004).
102. Endre ZH, Pickering JW. Biomarkers and creatinine in AKI: the trough of disillusionment or the slope of enlightenment? Kidney Int. (2013) (In press).
103. Benöhr P, Grenz A, Hartmann JT, Müller GA, Blaschke S. Cystatin C - a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press. Res. 29(1), 32-35 (2005).
104. Bonventre JV, Vaidya VS, Schmouder R, Feig P, Dieterle F. Next-generation biomarkers for detecting kidney toxicity. Nat. Biotech. 28(5), 436-440 (2010).
105. Stevens LA, Levey AS. Measurement of kidney function. Med. Clin. North Am. 89(3), 457-473 (2005).
106. Stevens LA, Schmid CH, Greene T et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 75(6), 652-660 (2009).
107. Knight EL, Verhave JC, Spiegelman D et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 65(4), 1416-1421 (2004).
108. Vinge E, Lindergård B, Nilsson-Ehle P, Grubb A. Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand. J. Clin. Lab. Invest. 59(8), 587-592 (1999).
109. Chew-Harris JSC, Florkowski CM, George PM, Elmslie JL, Endre ZH. The relative effects of fat versus muscle mass on cystatin C and estimates of renal function in healthy young men. Ann. Clin. Biochem. 50(Pt 1), 39-46 (2012).
110. Baxmann AC, Ahmed MS, Marques NC et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin. J. Am. Soc. Nephrol. 3(2), 348-354 (2008).
111. Jacobsen FK, Christensen CK, Mogensen CE, Andreasen F, Heilskov NS. Pronounced increase in serum creatinine concentration after eating cooked meat. BMJ 1(6170), 1049-1050 (1979).
112. Preiss DJ, Godber IM, Lamb EJ, Dalton RN, Gunn IR. The influence of a cooked-meat meal on estimated glomerular filtration rate. Ann. Clin. Biochem. 44(Pt 1), 35-42 (2006).
113. Koçak H, Oner-Iyidogan Y, Gürdöl F, Koçak T, Esin D. The relation between serum MDA and cystatin C levels in chronic spinal cord injury patients. Clin. Biochem. 38(11), 1034-1037 (2005).
114. Dubb JW, Stote RM, Familiar RG, Lee K, Alexander F. Effect of cimetidine on renal function in normal man. Clin. Pharmacol. Ther. 24(1), 76-83 (1978).
115. Berglund F, Killander J, Pompeius R. Effect of trimethoprim- sulfamethoxazole on the renal excretion of creatinine in man. J. Urol. 114(6), 802-808 (1975).
116. Kimmel M, Braun N, Alscher MD. Influence of thyroid function on different kidney function tests. Kidney Blood Press. Res. 35(1), 9-17 (2012).
117. ClinicalTrials.gov. www.clinicaltrials.gov
118. Australian New Zealand Clinical Trials Registry. www.anzctr.org.au
119. US FDA guidance for industry bioanalytical method validation. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm070107.pdf